Table 1.
Patient characteristics at baseline.
| RA (n = 95) | axSpA (n = 69) | PsA (n = 69) | Total (n = 233) | |
|---|---|---|---|---|
| Age [years], mean (SD) | 54.8 (15.3) | 42.5 (12.4) | 51.6 (10.9) | 50.2 (14.2) |
| Female, n (%) | 78 (82.1) | 30 (43.5) | 41 (59.4) | 149 (64.0) |
| Unemployed, n (%) | 46 (48.4) | 16 (23.2) | 18 (26.1) | 80 (34.3) |
| BMI, median (Q1, Q3) | 24.7 (22.2, 28.6) | 24.8 (22.9, 29.1) | 26.8 (24.5, 30.8) | 25.3 (23.1, 29.5) |
| Comorbidities, n (%) | ||||
| 0 | 54 (56.8) | 45 (65.2) | 44 (63.8) | 143 (61.4) |
| 1–2 | 28 (29.5) | 20 (29.0) | 16 (23.2) | 64 (27.5) |
| 3–5 | 12 (12.6) | 3 (4.4) | 5 (7.3) | 20 (8.6) |
| ≥6 | 1 (1.1) | 1 (1.5) | 4 (5.8) | 6 (2.6) |
| Previous biological therapy, n (%) | ||||
| 0 | 70 (73.7) | 53 (76.8) | 57 (82.6) | 180 (77.3) |
| 1 | 14 (14.7) | 10 (14.5) | 10 (14.5) | 34 (14.6) |
| 2+ | 11 (11.6) | 6 (8.7) | 2 (2.9) | 19 (8.2) |
| bDMARD at baseline, n (%) | 8 (8.4) | 7 (10.1) | 6 (8.7) | 21 (9.0) |
| Discontinued | 8 (8.4) | 7 (10.1) | 6 (8.7) | 21 (9.0) |
| csDMARD at baseline, n (%) | 85 (89.5) | 10 (14.5) | 39 (56.5) | 134 (57.5) |
| Continued | 30 (31.6) | 5 (7.2) | 21 (30.4) | 56 (24.0) |
| Discontinued | 50 (52.6) | 5 (7.2) | 17 (24.6) | 72 (30.9) |
| Unknown | 5 (5.3) | 0 (0.0) | 1 (1.4) | 6 (2.6) |
| tsDMARD at baseline, n (%) | 0 (0.0) | 0 (0.0) | 3 (4.3) | 3 (1.3) |
| Discontinued | 0 (0.0) | 0 (0.0) | 3 (4.3) | 3 (1.3) |
| Glucocorticoids at baseline, n (%) | 12 (12.6) | 7 (10.1) | 5 (7.2) | 24 (10.3) |
| Continued | 3 (3.2) | 2 (2.9) | 3 (4.3) | 8 (3.4) |
| Discontinued | 9 (9.5) | 5 (7.2) | 2 (2.9) | 16 (6.9) |
axSpA, axial spondyloarthritis; bDMARD, biologic disease-modifying anti-rheumatic drug; BMI, body mass index; csDMARD, conventional synthetic disease-modifying anti-rheumatic drug; PsA, psoriatic arthritis; Q1, first quartile; Q3, third quartile; RA, rheumatoid arthritis; SD, standard deviation; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.